These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 9506732)

  • 1. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
    Di Somma C; Colao A; Di Sarno A; Klain M; Landi ML; Facciolli G; Pivonello R; Panza N; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Mar; 83(3):807-13. PubMed ID: 9506732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
    Colao A; Di Somma C; Loche S; Di Sarno A; Klain M; Pivonello R; Pietrosante M; Salvatore M; Lombardi G
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus.
    Pivonello R; Faggiano A; Di Somma C; Klain M; Filippella M; Salvatore M; Lombardi G; Colao A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2349-52. PubMed ID: 10404801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
    Colao A; Di Somma C; Pivonello R; Loche S; Aimaretti G; Cerbone G; Faggiano A; Corneli G; Ghigo E; Lombardi G
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease.
    Di Somma C; Colao A; Pivonello R; Klain M; Faggiano A; Tripodi FS; Merola B; Salvatore M; Lombardi G
    Clin Endocrinol (Oxf); 1998 May; 48(5):655-62. PubMed ID: 9666879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of bone turnover and bone mineral density in hyperprolactinemic amenorrheic women.
    Shaarawy M; El-Dawakhly AS; Mosaad M; El-Sadek MM
    Clin Chem Lab Med; 1999 Apr; 37(4):433-8. PubMed ID: 10369115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
    De Rosa M; Colao A; Di Sarno A; Ferone D; Landi ML; Zarrilli S; Paesano L; Merola B; Lombardi G
    Eur J Endocrinol; 1998 Mar; 138(3):286-93. PubMed ID: 9539303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ; Chesnut CH; Mallinak NJ
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Femoral neck osteopenia in patients with inflammatory bowel disease.
    Pollak RD; Karmeli F; Eliakim R; Ackerman Z; Tabb K; Rachmilewitz D
    Am J Gastroenterol; 1998 Sep; 93(9):1483-90. PubMed ID: 9732930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.
    Hermus AR; Smals AG; Swinkels LM; Huysmans DA; Pieters GF; Sweep CF; Corstens FH; Kloppenborg PW
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2859-65. PubMed ID: 7559865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.
    Grinspoon S; Baum H; Lee K; Anderson E; Herzog D; Klibanski A
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3864-70. PubMed ID: 8923830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures.
    Mitra D; Elvins DM; Collins AJ
    J Rheumatol; 1999 Oct; 26(10):2201-4. PubMed ID: 10529140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome.
    Fairfield WP; Finkelstein JS; Klibanski A; Grinspoon SK
    J Clin Endocrinol Metab; 2001 May; 86(5):2020-6. PubMed ID: 11344201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease.
    Dresner-Pollak R; Karmeli F; Eliakim R; Ackerman Z; Rachmilewitz D
    Am J Gastroenterol; 2000 Mar; 95(3):699-704. PubMed ID: 10710060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
    Guo CY; Weetman AP; Eastell R
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.